ANGLE plc , a global leader in liquid biopsy, has announced a collaboration with Myriad Genetics, Inc. , a precision medicine company specializing in molecular diagnostics.
As part of the agreement, ANGLE’s R&D team will process cancer patient blood samples using the Parsortix® system to capture and harvest intact circulating tumour cells (CTCs) for downstream molecular analysis. The results will compare CTC-derived DNA with matched patient tissue samples using Myriad Genetics’ established tissue-based assays.
While further details remain confidential, the partnership aims to expand tissue-based companion diagnostics into simple blood-based testing. ANGLE CEO Andrew Newland highlighted that this collaboration could significantly improve access to actionable genomic data, enabling more personalized cancer treatment options.